 |
Previous Article | Next Article 
The Journal of Neuroscience, November 1, 2002, 22(21):9595-9603
Dopamine D3 Receptor Antagonism Inhibits
Cocaine-Seeking and Cocaine-Enhanced Brain Reward in Rats
Stanislav R.
Vorel1, 2,
Charles R.
Ashby Jr4,
Mousumi
Paul5,
Xinhe
Liu3,
Robert
Hayes2,
Jim J.
Hagan6,
Derek N.
Middlemiss6,
Geoffrey
Stemp6, and
Eliot L.
Gardner1, 2, 3
1 Intramural Research Program, National Institute on
Drug Abuse, Baltimore, Maryland 21224, Departments of
2 Neuroscience and 3 Psychiatry and Behavioral
Sciences, Albert Einstein College of Medicine, Bronx, New York 10461, 4 Department of Pharmaceutical Sciences, College of
Pharmacy and Allied Health Professions, Saint John's University,
Jamaica, New York 11439, 5 Eon Laboratories, Laurelton, New
York 11413, and 6 Psychiatry Centre of Excellence for Drug
Discovery, GlaxoSmithKline, Harlow, Essex CM19 5AW, United Kingdom
The dopamine D3 receptor is preferentially localized to
the mesocorticolimbic dopaminergic system and has been hypothesized to
play a role in cocaine addiction. To study the involvement of the
D3 receptor in brain mechanisms and behaviors commonly assumed to be involved in the addicting properties of cocaine, the
potent and selective D3 receptor antagonist
trans-N-[4-[2-(6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl] cyclohexyl]-4-quinolininecarboxamide
(SB-277011-A) was administered to laboratory rats, and the following
measures were assessed: (1) cocaine-enhanced electrical
brain-stimulation reward, (2) cocaine-induced conditioned place
preference, and (3) cocaine-triggered reinstatement of cocaine seeking
behavior. Systemic injections of SB-277011-A were found to (1) block
enhancement of electrical brain stimulation reward by cocaine, (2)
dose-dependently attenuate cocaine-induced conditioned place
preference, and (3) dose-dependently attenuate cocaine-triggered
reinstatement of cocaine seeking behavior. Thus, D3
receptor blockade attenuates both the rewarding effects of cocaine and
cocaine-induced drug-seeking behavior. These data suggest an important
role for D3 receptors in mediating the addictive properties
of cocaine and suggest that blockade of dopamine D3 receptors may constitute a new and useful target for prospective pharmacotherapies for cocaine addiction.
Key words:
cocaine; addiction; dopamine; mesolimbic; mesocorticolimbic; D3 receptor; D3 antagonist; brain stimulation reward; BSR; self-stimulation; ICSS; conditioned
place preference; CPP; self-administration; reinstatement; relapse
Copyright © 2002 Society for Neuroscience 0270-6474/02/22219595-09$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
J. L. Martelle, R. Claytor, J. T. Ross, B. A. Reboussin, A. H. Newman, and M. A. Nader
Effects of Two Novel D3-Selective Compounds, NGB 2904 [N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the Reinforcing and Discriminative Stimulus Effects of Cocaine in Rhesus Monkeys
J. Pharmacol. Exp. Ther.,
May 1, 2007;
321(2):
573 - 582.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Gyertyan, B. Kiss, K. Gal, I. Laszlovszky, A. Horvath, L. I. Gemesi, K. Saghy, G. Pasztor, M. Zajer, M. Kapas, et al.
Effects of RGH-237 [N-{4-[4-(3-Aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an Orally Active, Selective Dopamine D3 Receptor Partial Agonist in Animal Models of Cocaine Abuse
J. Pharmacol. Exp. Ther.,
March 1, 2007;
320(3):
1268 - 1278.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Luo, H. R. Kranzler, L. Zuo, S. Wang, N. J. Schork, and J. Gelernter
Multiple ADH genes modulate risk for drug dependence in both African- and European-Americans
Hum. Mol. Genet.,
February 15, 2007;
16(4):
380 - 390.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Vengeliene, F. Leonardi-Essmann, S. Perreau-Lenz, P. Gebicke-Haerter, K. Drescher, G. Gross, and R. Spanagel
The dopamine D3 receptor plays an essential role in alcohol-seeking and relapse
FASEB J,
November 1, 2006;
20(13):
2223 - 2233.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Hammad and J. J. Wagner
Dopamine-Mediated Disinhibition in the CA1 Region of Rat Hippocampus via D3 Receptor Activation
J. Pharmacol. Exp. Ther.,
January 1, 2006;
316(1):
113 - 120.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. J. Vocci, J. Acri, and A. Elkashef
Medication Development for Addictive Disorders: The State of the Science
Am J Psychiatry,
August 1, 2005;
162(8):
1432 - 1440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. T. Collins, J. M. Witkin, A. H. Newman, K. A. Svensson, P. Grundt, J. Cao, and J. H. Woods
Dopamine Agonist-Induced Yawning in Rats: A Dopamine D3 Receptor-Mediated Behavior
J. Pharmacol. Exp. Ther.,
July 1, 2005;
314(1):
310 - 319.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Le Foll and S. R. Goldberg
Cannabinoid CB1 Receptor Antagonists as Promising New Medications for Drug Dependence
J. Pharmacol. Exp. Ther.,
March 1, 2005;
312(3):
875 - 883.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. A. Champagne, P. Chretien, C. W. Stevenson, T. Y. Zhang, A. Gratton, and M. J. Meaney
Variations in Nucleus Accumbens Dopamine Associated with Individual Differences in Maternal Behavior in the Rat
J. Neurosci.,
April 28, 2004;
24(17):
4113 - 4123.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|